This study investigated potential mechanisms of azole resistance among Candida albicans from animals, including efflux pump activity, ergosterol content and gene 
| INTRODUCTION
The genus Candida gathers yeast that compose animal and human microbiota that may cause opportunistic infections. [1] [2] [3] [4] Many of these yeast are potentially pathogenic, of which C. albicans is the most important in human and veterinary medicine. 5, 6 Azole-resistant C. albicans strains have been isolated from healthy and diseased animal hosts with no history of prior antifungal treatment.
1,2,4
In strains from humans, it is known that azole resistance is a multifactorial phenomenon. Resistance commonly emerges from long periods of antifungal treatment/prophylaxis, as a result of genetic mutations or increased expression of genes involved in the biosynthesis of ergosterol (eg ERG3 and ERG11) and/or in the activity of efflux pumps of the Major facilitator superfamily (MFS) and the ATP-binding cassette (ABC). 7, 8 ABC pumps are widely described as the main cause of azole resistance in C. albicans from humans. 9, 10 These strains present higher mRNA levels of the efflux pump genes for Candida drug resistance 1 (CDR1) and 2 (CDR2), even after short exposure to antifungal drugs. 8, [10] [11] [12] Furthermore, the increased expression of the multidrug resistant 1 (MDR1) gene of MFS, which encodes proton-dependent efflux pumps, may be associated with specific fluconazole resistance. 13 Finally, the increased expression and/or polymorphism/mutation of ERG11 gene may lead to increased amount of the enzyme Erg11p or decreased affinity between azoles and this enzyme, respectively, resulting in azole resistance.
11,14,15
The emergence of resistance among C. albicans from animals is not well understood. Despite reports of resistance to azoles in these strains, 1,2,16-18 the contribution of the efflux pump encoding genes CDR and MDR and the gene involved in ergosterol biosynthesis ERG11
had never been assessed in animal strains. It is hypothesised that the development of resistance in these fungi may be a way to adapt to stress in the environment and/or within animal hosts. 19 Thus, this study aimed to investigate the role of efflux pumps, ergosterol content and expression of the genes CDR1, CDR2, MDR1 and ERG11 in the development of azole resistance among C. albicans from animals.
| MATERIALS AND METHODS

| Assessed strains and antifungal susceptibility testing
Thirty azole-resistant C. albicans strains from animals were analysed in this study. The animal strains were recovered from rheas (Rhea americana, n=9), porcupine (Coendou prehensilis, n=1), sheep (Ovis aries, n=6), cockatiels (Nymphicus hollandicus, n=2), dogs (Canis lupus familiaris, n=3) and manatees (Trichechus manatus, n=9). One strain recovered from rhea was susceptible to all tested azoles and was chosen as the control strain for gene expression in this study. Almost all tested C. albicans strains were colonising different mucosal sites of healthy animals, except for that from porcupine, which was isolated from an invasive fungal infection. In addition, it is important to highlight that none of the animal hosts had a history of antifungal treatment. These strains belong to the fungal collection of the Specialized Medical Mycology Center of the Federal University of Ceará and are stored at −20°C.
The inclusion criterion of the strains was the presence of resistance to at least one azole derivative, but all tested strains were susceptible to amphotericin B and caspofungin. This inclusion criterion was based on the frequent isolation of azole-resistant Candida strains from animals. As previously stated, one azole-susceptible strain from a rhea was used as control strain (calibrator for qPCR). Four human strains of C. albicans (two azole resistant-C1 and C2, and two azole susceptible-C3 and C4) were added for comparative purposes in different tests of this study. Antifungal susceptibility was reassessed using broth microdilution, following the M27-A3 document of CLSI, 20 as previously reported. 1,2 The assay was performed in duplicate and the strain C. parapsilosis ATCC 22019 was used as quality control. 
| Efflux of rhodamine 6G
Rhodamine 6G (R6G) acts as a substrate for CDR pumps. 21 This fluorescent dye is used as a tool for the evaluation of the efflux activity of these pumps. In this step, the efflux of rhodamine 6G was tested by the methodology described by Rocha et al., [22] with modifications. 
| Ergosterol content
The ergosterol content of six randomly selected strains was deter- and incubated for 1 h at 95°C in a waterbath. After cooling, 1 mL of n-hexane was added and the tubes were vigorously shaken for 5 min.
Subsequently, the tubes were centrifuged at 3500 g for 5 min and the upper organic layer transferred to a new tube and mixed with 1 mL of n-hexane. Then, absorbance of this solution was measured in duplicate at 261, 273, 282 and 294 nm in a spectrophotometer. For comparative purposes, two susceptible C. albicans strains from humans (C3 and C4) were added in this step of the research.
| Total RNA extraction and gene expression analysis
Total RNA was prepared in triplicate from three-pooled sample groups using the RNeasy mini kit (Qiagen Sci., Germantown, MD, USA) according to the manufacturer's instructions. Briefly, the strains were grown in YEPD broth (0.5% yeast extract, 1% peptone, 2% dextrose) at 30°C for 24 h, until reaching the mid-log growth phase. Then, ) and the efficiency (E) of the PCR amplifications, standard curves were generated for each gene using serial dilutions of cDNA preparations. Specificity of each reaction was ascertained after finishing the amplification protocol. This was achieved by performing the melting procedure (55-95°C, starting fluorescence acquisition at 55°C and taking measurements at 10 s intervals until the temperature reached 95°C). As negative controls, samples with RNA but without reverse transcriptase were used. The relative quantification was performed using the 2 −ΔΔCq method. 25 Target gene expression was normalised against ACT1 transcript levels. Overexpression was considered when the expression level of target genes of the resistant strains was statistically higher than that of the susceptible calibrator strain.
Threshold and Cq (threshold cycle) values were automatically determined by the ReAlplex 2.2 software (Eppendorf), using default parameters. As previously stated, one azole-susceptible C. albicans strain from a rhea was used as control strain (calibrator for qPCR). For comparative purposes, two resistant C. albicans strains (C1 and C2) from humans were added in this step.
| Statistical analysis
Efflux pump activity, ergosterol content and expression levels of CDR1, CDR2, MDR1 and ERG11 were subjected to Log(Y) transformation, assuming a Gaussian distribution, and expressed as mean ± standard error (SE) of three measurements. These data were then compared using a two-way analysis of variance (AnOvA), followed by 
| RESULTS
The poststorage reevaluation of the antifungal susceptibility demonstrated stability of the azole-resistant phenotype of these animal C. albicans strains (Table 1 ). Resistance to fluconazole and itraconazole was observed in 23 and 26 isolates respectively.
Rhodamine 6G (R6G) test was used to detect efflux pump activity. Figure 1 Ergosterol content was determined for eight randomly selected strains at four different wavelengths (261, 273, 282, 294 nm). There were no differences between azole-resistant or susceptible strains, when they were exposed or not to fluconazole. These findings suggest that there were no changes in the final amounts of ergosterol or in the sterol profile extracted from the strains, even under the stress of exposure to subinibitory doses of fluconazole.
CDR1, CDR2, MDR1
and ERG11 expression profiles for all strains are presented in Figure 2 . Twenty-two out of thirty (22/ 
| DISCUSSION
This study investigated CDR1, CDR2, MDR1 and ERG11 gene expression in C. albicans strains from animals with antifungal drug resistance. Previous works of our group indicated the involvement of ATP-dependent efflux pumps in the phenotype of azole resistance, as exposure of azole-resistant strains to an efflux pump inhibitor (promethazine) reversed the antifungal resistance. 1, 26 In addition, some of the strains tested in this study showed cross-resistance to different azole drugs, which also suggests the involvement of ATP-dependent efflux pumps, since all azole drugs can act as substrates for these pumps. Antifungal resistance in veterinary strains has been reported in several studies, 1,2,17,18 but little is known about the molecular mechanisms that lead to azole resistance among these strains.
In an attempt to assess possible resistance mechanisms in the studied strains, we performed the rhodamine 6G efflux assay. This substance acts as substrate for ATP-dependent efflux pumps. In This hypothesis seems reasonable, but other studies are necessary to better understand the dynamics of ergosterol biosynthesis and adaptation in C. albicans isolates, as suggested by Lv et al. [28] .
In human strains, the emergence of resistance is attributed to the misuse or chronic use of azoles in specific patient groups 29 On the basis of this study, we conclude that resistance to azoles in C. albicans strains from animals mainly involves the enhanced activity of efflux pumps and CDR1 and CDR2 gene overexpression.
Furthermore, the other classically studied genes MDR1 and ERG11
were also overexpressed in the tested strains, suggesting that azole resistance in C. albicans strains from healthy and diseased animal hosts with no history of antifungal treatment is likely a result of multifactorial mechanisms, including increased efflux pump activity and the overexpression of different genes.
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